ABSI News

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

Seekingalpha | 5 months ago

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.

Zacks | 5 months ago

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Seekingalpha | 5 months ago

Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201

Absci Corporation is downgraded to Hold due to a lack of differentiation for ABS-101 and a strategic pivot to ABS-201. ABS-101 failed to outperform 2nd-generation TL1A candidates, leading to halted internal development and a search for external partnerships. Focus shifts to ABS-201 for androgenetic alopecia, but meaningful efficacy data won't arrive until late 2026 or early 2027.

Seekingalpha | 6 months ago

Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript

Seekingalpha | 6 months ago

Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago.

Zacks | 6 months ago

Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Seekingalpha | 6 months ago

Absci Corporation (ABSI) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seekingalpha | 7 months ago

Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 9 months ago

Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript

Seekingalpha | 10 months ago

ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study

Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.

Zacks | 10 months ago

Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Absci Corporation ( ABSI ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Sean McClain - Founder, CEO, President & Director Presentation Operator It's my pleasure to now introduce Sean McClain, CEO; and Zach Jonasson, CFO of Absci Corporation. Just a reminder, there will be a 20-minutes presentation following with 5 minutes Q&A.

Seekingalpha | 10 months ago